A year after a Supreme Court opinion put the final nail in the coffin for Amarin’s fish-oil heart drug, the biotech is making some changes to keep its doors open.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,